Trials / Unknown
UnknownNCT05735262
pBFS Guided Precision Neuromodulation Treatment for ASD
Personalized Brain Functional Sectors (pBFS) Guided Precision Neuromodulation Treatment for Autism Spectrum Disorder (ASD): a Single-center, Sham-controlled, Double-blinded, Randomized Clinical Trial Study
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Changping Laboratory · Academic / Other
- Sex
- All
- Age
- 6 Years – 30 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to evaluate the neuromodulation (i.e., iTBS) effectiveness for treating autism spectrum disorder (ASD) by targeting at the pBFS-guided executive function brain network or social brain network.
Detailed description
Autism spectrum disorder is characterized by executive function deficiency and social interaction difficulty. Using the developed technique, personalized brain functional sectors (pBFS), we could precisely identify individualized brain function networks based on the resting-state functional MRI scan. A tailored dorsal lateral prefrontal cortex (DLPFC) region situated within the executive function network and a tailored dorsal medial prefrontal cortex (DMPFC) region situated within the social network will be selected as intervention targets. The participants will be equally randomized to the following three groups, active iTBS to the left DLPFC, active iTBS to the left DMPFC, and sham iTBS to either the left DLPFC or left DMPFC at a ratio of 2:2:1:1. Each participant will receive 1800 pulse active or sham iTBS (100% RMT) in each session, 3 sessions daily, 5 days per week for 8 weeks, as well as background behavioral training between iTBS sessions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | active iTBS | Each participant will receive 1800 pulse active iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks. |
| DEVICE | sham iTBS | Each participant will receive 1800 pulse sham iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks. |
Timeline
- Start date
- 2023-03-07
- Primary completion
- 2024-03-01
- Completion
- 2025-01-01
- First posted
- 2023-02-21
- Last updated
- 2023-05-30
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05735262. Inclusion in this directory is not an endorsement.